The Metabolic-Immunotherapy Connection: Why Glucose, Insulin, Ketones — and Liver Health — Matter

By Editorial Team

Cancer treatment is increasingly moving beyond the idea that tumors are driven only by genetic mutations. A growing body of research now suggests that metabolism — including glucose levels, insulin signaling, mitochondrial function, fatty liver disease, and ketone metabolism — may strongly influence how cancers grow, spread, and respond to treatment.

One of the clearest examples of this connection is now emerging in liver cancer, where metabolic disease has become one of the fastest-growing causes worldwide.

Researchers are beginning to explore whether improving metabolic health could potentially influence:

  • cancer risk,

  • tumor progression,

  • inflammation,

  • and even responses to immunotherapy.

The Metabolic-Immunotherapy Connection

The Global Rise of Metabolic Disease

Modern metabolic disease includes:

  • obesity

  • insulin resistance

  • type 2 diabetes

  • metabolic syndrome

  • fatty liver disease

These conditions are now increasingly linked to cancer development.

Particularly:

  • liver cancer

  • colorectal cancer

  • pancreatic cancer

  • breast cancer

  • endometrial cancer

The liver sits at the center of metabolism, making it especially vulnerable to chronic metabolic dysfunction.

Fatty Liver Disease and Cancer

A major emerging driver of liver cancer is:

  • MASLD (Metabolic dysfunction-associated steatotic liver disease)

Previously called:

  • NAFLD (Non-alcoholic fatty liver disease)

More advanced inflammatory disease is called:

  • MASH (Metabolic dysfunction-associated steatohepatitis)

These conditions are closely associated with:

  • obesity

  • insulin resistance

  • high fructose intake

  • visceral fat accumulation

  • chronic inflammation

The Metabolic Disease → Liver Cancer Pathway

Obesity/Insulin Resistance → Fatty Liver → Chronic Inflammation → Fibrosis/Cirrhosis → Liver Cancer.

Over time, chronic metabolic stress may lead to:

  • liver inflammation

  • fibrosis

  • cirrhosis

  • DNA damage

  • immune dysfunction

This creates an environment favorable for hepatocellular carcinoma (HCC), the most common type of liver cancer.

Why Liver Cancer Is Increasing Worldwide

Historically, liver cancer was mainly linked to:

  • hepatitis B

  • hepatitis C

  • alcohol-related cirrhosis

Today, metabolic disease is becoming a dominant driver.

Many experts believe the global obesity and diabetes epidemic may substantially increase liver cancer incidence over the coming decades.

This represents a major shift in oncology.

The Liver Is an Immune Organ

The liver is not only a metabolic organ — it is also deeply involved in immune regulation.

It constantly filters:

  • nutrients

  • toxins

  • bacteria

  • inflammatory molecules

Because of this, chronic liver disease may profoundly affect:

  • immune surveillance

  • inflammation

  • T-cell activity

  • tumor immunity

Insulin Resistance and Cancer Signaling

Insulin resistance often causes chronically elevated insulin levels.

High insulin may activate:

  • PI3K/AKT/mTOR pathways

  • IGF-1 signaling

  • inflammatory cascades

These pathways are heavily involved in cancer biology.

High Insulin → mTOR/IGF-1 Activation →  Tumor Growth and Survival.

Many tumors exploit these growth pathways to support:

  • proliferation

  • angiogenesis

  • metastasis

  • treatment resistance

Glucose, Lactate and Immune Suppression

Many tumors rely heavily on glucose metabolism.

This often leads to:

  • lactate accumulation

  • acidic microenvironments

  • T-cell exhaustion

Tumor Glycolysis → Lactate Production → Immune Suppression.

In liver cancer, this metabolic-immune interaction may be especially important because:

  • the liver already regulates nutrient metabolism,

  • immune tolerance,

  • and inflammatory signaling.

Why Immunotherapy Sometimes Works Poorly in Metabolic Disease

Modern immunotherapy drugs include:

  • Pembrolizumab

  • Nivolumab

  • Atezolizumab

These drugs depend on functional immune responses.

However, metabolic disease may contribute to:

  • chronic inflammation

  • dysfunctional T-cells

  • immune exhaustion

  • altered cytokine signaling

Some researchers suspect severe metabolic dysfunction may reduce immunotherapy effectiveness in certain patients.

This remains an active area of investigation.

Liver Cancer and Immunotherapy

Immunotherapy has become increasingly important in advanced liver cancer treatment.

Combination regimens such as:

  • Atezolizumab plus Bevacizumab

have improved outcomes in some patients with advanced hepatocellular carcinoma.

But response rates remain variable.

Researchers are now investigating whether:

  • obesity

  • fatty liver disease

  • insulin resistance

  • gut microbiome composition

may influence which patients respond best.

Ketones and Metabolic Flexibility

Ketones are alternative fuel molecules produced during:

  • fasting

  • carbohydrate restriction

  • ketogenic diets

The primary ketone body is:

  • beta-hydroxybutyrate (BHB)

Some scientists hypothesize that ketosis may:

  • lower insulin levels

  • reduce glucose availability

  • decrease inflammation

  • improve mitochondrial efficiency

However:

evidence in cancer patients remains preliminary.

Mitochondria, Fatty Liver and Immune Health

Mitochondrial dysfunction appears central to both:

  • metabolic disease

  • cancer progression

In fatty liver disease, mitochondria often become:

  • overloaded

  • damaged

  • oxidatively stressed

This may worsen:

  • inflammation

  • fibrosis

  • immune dysregulation

Healthy mitochondrial function is also essential for:

  • activated T-cells

  • NK cells

  • immune persistence

The Gut-Liver-Immune Axis

Another emerging area is the gut microbiome.

The liver receives blood directly from the intestines through the portal vein.

This means:

  • gut bacteria,

  • endotoxins,

  • and dietary metabolites

may directly influence liver inflammation and immune signaling.

Researchers are now studying whether:

  • probiotics,

  • fiber,

  • microbiome-targeted therapies,

  • or dietary interventions

could influence cancer immunity.

GLP-1 Drugs and Liver Cancer Prevention?

Newer metabolic drugs such as:

  • Semaglutide

  • Tirzepatide

may improve:

  • insulin sensitivity

  • weight loss

  • fatty liver disease

  • systemic inflammation

Researchers are now investigating whether these metabolic improvements could potentially reduce long-term cancer risk. Large-scale outcome data are still evolving.

Precision Oncology Is Becoming Systems Oncology

Cancer increasingly appears to involve:

  • genetics

  • metabolism

  • immune function

  • inflammation

  • microbiome interactions

  • hormonal signaling

Rather than viewing tumors as isolated masses, researchers now study:

the entire tumor ecosystem.

Liver cancer may become one of the clearest examples of this systems-based model.

Key Takeaways

  • Metabolic disease is becoming a major driver of liver cancer worldwide.

  • Fatty liver disease may progress from inflammation to fibrosis, cirrhosis, and cancer.

  • Insulin resistance and glucose metabolism influence both tumor biology and immune function.

  • Liver cancer sits at the intersection of metabolism, immunity, and inflammation.

  • Immunotherapy responses may partly depend on metabolic health and immune fitness.

  • Ketogenic diets, fasting, microbiome interventions, and metabolic therapies remain experimental but increasingly studied.

Final Thoughts

The relationship between metabolism and cancer is no longer considered fringe science.

Today, many researchers believe that:

metabolic dysfunction may help shape the tumor microenvironment itself.

Liver cancer illustrates this especially well because the liver controls:

  • glucose metabolism,

  • lipid metabolism,

  • detoxification,

  • immune regulation,

  • and inflammatory signaling simultaneously.

In the future, oncology may increasingly combine:

  • immunotherapy,

  • metabolic medicine,

  • liver health optimization,

  • microbiome science,

  • and AI-driven biomarker analysis

into more personalized cancer treatment strategies.


References:

Diet and Cancer Metabolism: Why Nutrition Is Emerging as a Key Focus in Oncology

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...
Read more